Equities Analysts Offer Predictions for CGTX FY2026 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Brookline Capital Markets raised their FY2026 earnings estimates for shares of Cognition Therapeutics in a report issued on Friday, August 7th. Brookline Capital Markets analyst F. Ahmed now anticipates that the company will earn ($0.42) per share for the year, up from their prior forecast of ($0.44). The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.34) per share.

Cognition Therapeutics (NASDAQ:CGTX) last announced its earnings results on Thursday, August 6th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02.

Several other research analysts also recently issued reports on CGTX. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Cognition Therapeutics in a report on Monday, June 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Wednesday, June 24th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cognition Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $3.33.

Cognition Therapeutics Price Performance

CGTX opened at $1.02 on Wednesday. The stock has a market capitalization of $96.99 million, a P/E ratio of -6.00 and a beta of 1.77. The company’s 50 day simple moving average is $1.12 and its 200-day simple moving average is $1.11. Cognition Therapeutics has a one year low of $0.55 and a one year high of $3.83.

Institutional Investors Weigh In On Cognition Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Gamco Investors INC. ET AL acquired a new position in Cognition Therapeutics in the third quarter valued at approximately $27,000. Essex Financial Services Inc. acquired a new stake in Cognition Therapeutics during the 4th quarter worth $27,000. Private Management Group Inc. acquired a new stake in Cognition Therapeutics during the 3rd quarter worth $32,000. Marshall Wace LLP bought a new stake in shares of Cognition Therapeutics during the 4th quarter valued at $37,000. Finally, Bryn Mawr Trust Advisors LLC bought a new stake in shares of Cognition Therapeutics during the 2nd quarter valued at $33,000. 43.35% of the stock is owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.